ライフサイエンスコーパス: adrenergic-blocking agent

1 ne-recommended medications (aspirin and beta-adrenergic blocking agents).

2 ing chronic heart failure patients with beta-adrenergic blocking agents.

3 h either alpha-2 adrenergic agonists or beta adrenergic blocking agents.

4 iffer between the investigated types of beta-adrenergic blocking agents.

5 ed; seven patients (41%) were receiving beta-adrenergic blocking agents.

6 in, p < 0.0001) and more often received beta-adrenergic blocking agents (49% vs. 14%, p < 0.0001).

7 Beta-adrenergic blocking agents (abbreviated as beta-blockers

8 However, for the subset of patients on beta-adrenergic blocking agents after CABG, there was a trend

9 New medical treatments, including alpha-adrenergic blocking agents and 5 alpha-reductase inhibit

10 ng-term health outcomes associated with beta-adrenergic blocking agents and diltiazem treatment for u

11 mean age 57 years) who were not taking beta-adrenergic blocking agents and were referred for symptom

12 l Question: Does nurse-led titration of beta-adrenergic blocking agents, angiotensin-converting enzym

13 The use of aspirin, beta-adrenergic blocking agents, angiotensin-converting enzym

14 s with such capability when aspirin and beta-adrenergic blocking agents are given appropriately and t

15 Beta-adrenergic blocking agents are used in most patients for

16 eatments for patients with AMI, such as beta-adrenergic blocking agents, aspirin and immediate reperf

17 or the use of concomitant medications (beta-adrenergic blocking agents, calcium channel blocking age

18 of several studies with the alpha- and beta-adrenergic blocking agent carvedilol demonstrated a sign

19 The short-acting beta1-selective adrenergic blocking agent, esmolol, was administrated du

20 lude initial therapy with a diuretic or beta-adrenergic blocking agent, for which reductions in morbi

21 Chronic treatment with beta-adrenergic blocking agents has been shown to improve lef

22 Beta-adrenergic blocking agents have been revalidated in rece

23 re also more likely to receive aspirin, beta-adrenergic blocking agents, heparin and nitrates (all p

24 edications such as aspirin, statins and beta-adrenergic blocking agents in conjunction with comprehen

25 in cardiomyopathy patients treated with beta-adrenergic blocking agents is controversial.

26 as designed to examine the effects of a beta-adrenergic blocking agent on the ischemic response to do

27 -converting enzyme (ACE) inhibitors and beta-adrenergic blocking agents on the remodeling process.

28 with stable angina pectoris receiving a beta-adrenergic blocking agent or calcium antagonist, or both

29 ment with either timolol, a nonspecific beta adrenergic blocking agent, or with para-aminoclonidine,

30 ns: patients with first MI, patients on beta-adrenergic blocking agents, patients with LVEF < or =30%

31 Phentolamine, an alpha-adrenergic blocking agent, prevents the C75-induced incr

32 group 1 patients had significantly less beta-adrenergic blocking agent use and higher ejection fracti

33 nalysis was performed to assess whether beta-adrenergic blocking agent use is associated with reduced

34 ltivariate analysis, the association of beta-adrenergic blocking agent use with reduced mortality rem

35 ts; After adjusting for age, gender and beta-adrenergic blocking agent use, multiple logistic regress

36 sely to prior myocardial infarction and beta-adrenergic blocking agent use.

37 Beta-adrenergic blocking agents were administered concurrentl

38 tensin-converting-enzyme inhibitors and beta-adrenergic-blocking agents were administered if the pati

39 A short-acting beta1-selective adrenergic blocking agent, when administered during card

40 Sotalol, a beta-adrenergic blocking agent with class III antiarrhythmic